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A 12-year-old female patient with biliary atresia underwent living donor liver transplantation (LDLT). Twelve months
after the LDLT, she developed acute hepatitis (alanine aminotransferase 584 IU/L) and was diagnosed with
disseminated varicella-zoster virus (VZV) infection with high level of serum VZV-DNA (1.5 × 105 copies/mL) and
generalized vesicular rash. She had received the VZV vaccination when she was 5-years-old and had not been
exposed to chicken pox before the LDLT, and her serum was positive for VZV immunoglobulin G at the time of
the LDLT. Although she underwent treatment with intravenous acyclovir, intravenous immunoglobulin, and
withdrawal of immunosuppressants, her symptoms worsened and were accompanied by disseminated intravascular
coagulation, pneumonia, and encephalitis. These complications required treatment in the intensive care unit
for 16 days. Five weeks later, her clinical findings improved, although her VZV-DNA levels remained high (8.5 ×
103copies/mL). Oral acyclovir was added for 2 weeks, and she was eventually discharged from our hospital on
day 86 after admission; she has not experienced a recurrence. In conclusion, although disseminated VZV infection
with multiple organ failure after pediatric LDLT is a life-threatening disease, it can be cured via an early diagnosis
and intensive treatment.
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VZV-DNA PCRBackground
Varicella-zoster virus (VZV) is a DNA virus that belongs
to the family of herpes viruses, and is the cause of both
chicken pox (as a primary infection) and herpes zoster,
which is a reactivation infection that is typically ob-
served in adults. Chicken pox is generally a mild disease,
VZV infection is known to be more severe in adolescent
patients, and although disseminated VZV infection is a
rare disease, it is potentially life-threating in patients with
immunosuppression after organ transplantation [1–4].
We had previously reported VZV infections after pediatric
living donor liver transplantation (LDLT), which was the
largest analysis of VZV infections after pediatric LDLT
[5–9]. Based on our findings, we concluded that we could* Correspondence: yn708@jichi.ac.jp
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creativecommons.org/publicdomain/zero/1.0/prevent the infection from developing into serious illness
via our pre-and post-transplant strategies. However, we
recently experienced a case of severe disseminated VZV
infection with multiple organ failure (MOF) after pediatric
LDLT, and successfully rescued the patient. Therefore
we report this case of disseminated VZV infection with
MOF after pediatric LDLT, and re-consider the pre-and
post-transplant strategies for preventing and treating
VZV infection.Case presentation
A 12-year-old female patient with biliary atresia under-
went LDLT using a left lobe graft from her ABO-
compatible father. She had received the VZV vaccination
when she was 5-years-old and she had not been exposed
to chicken pox before the LDLT. Her serum was positive
for VZV immunoglobulin G (IgG) (×160; Artus VZV-article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The patient’s skin rash with blisters, which were already
partially covered with scabs
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recipients’ cytomegalovirus (CMV) status was seronega-
tive (IgG-negative and IgM-negative) before the LDLT,
although the donor’s CMV status was seropositive (IgG-
positive [×1,500] and IgM-negative). Her immunosup-
pression regimen after LDLT consisted of tacrolimus
(FK), methylprednisolone (MP), and mycophenolate mo-
fetil (MMF). She did not receive prophylactic therapy for
CMV infection, and was evaluated each month for CMV
antigenemia (C7-HRP) [10].
Twelve months after the LDLT, she developed a fever
and back pain with generalized vesicular rash and was
admitted to our hospital 5 days later (Fig. 1). She had
not been exposed to any person with chicken pox, she
had not been receiving varicella-zoster immune globulin,
and she was negative for VZV-IgG antibodies at the
hospitalization. We subsequently diagnosed her as hav-














WBC white blood cell, RCB red blood cell, Hb hemoglobin, Ht hematocrit, Plt platele
AST aspartate transaminase, ALT alanine amino transaminase, ALP alkaline phosphat
total-bilirubin, D-Bil direct bilirubin, BUN blood urea nitrogen, Cre cretinine, CRP c-cr
time, PT-INR prothrombin time-international normalized ratio, Fib fibrinogen, FDP fib
EBV-DNA 12x102 copies/1O6WBC ⇒ EBV-DNA 12x102 copies/106 WBCthe PCR results for VZV-DNA (1.6 × 105 copies/mL). As
we could not investigate the strain type of the VZV, we
were unable to determine whether her infection was pri-
mary infection or secondary dissemination. In addition,
she exhibited signs of severe hepatic damage (alanine
aminotransferase: 584 IU/L) and disseminated intravascu-
lar coagulation (DIC) (Table 1). We considered perform-
ing a liver biopsy, although we chose not to perform the
biopsy, given her bleeding tendency. Based on the find-
ings, we diagnosed her with disseminated VZV infection
that was accompanied by acute hepatitis and DIC, and
started intensive treatment.
Although she underwent treatment with intravenous
acyclovir (30 mg/kg/day), intravenous immunoglobulin
(125 mg/kg/day), and withdrawal of all immunosuppres-
sants (FK, MP, and MMF), her symptoms worsened, and
she developed pneumonia that required artificial respira-
tory management for 11 days (Fig. 2). Based on the clin-
ical course, we assumed that this was VZV pneumonia,
although we could not perform a bronchoalveolar lavage
to confirm this hypothesis. On day 4 after admission,
she exhibited neutropenia (<1000/mm3), due to bone mar-
row suppression. On day 12, she experienced a generalized
tonic-clonic seizure. Although brain magnetic resonance
imaging did not reveal any abnormal findings, we sus-
pected encephalitis due to disseminated VZV infection
and considered performing a lumbar puncture, although
we chose not to perform the puncture, based on her unre-
solved bleeding tendency. Therefore, she remained in the
intensive care unit for 16 days, and as her symptoms
gradually improved, we resumed the oral immunosuppres-
sants (FK and MP) after 12 days of cessation. In addition,
on day 16, we changed the intravenous acyclovir toaged and disseminated intravascular coagulation
T-bil 3.14 mg/dl
D-Bil 1.54 mg/dl
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All of skin rash was
covered with scabs
Fig. 2 The patient’s clinical course. The patient exhibited severe hepatitis (alanine aminotransferase: 951 IU/mL), which gradually improved. PCR
testing for varicella-zoster virus (VZV) DNA revealed decreasing values after treatment with intravenous acyclovir in the first two weeks. However,
the VZV-DNA remained high and tended to be elevated after five weeks of antiviral therapy. Therefore we added prophylactic oral acyclovir for
two weeks after her clinical symptoms had improved. She was eventually discharged on day 86 after her admission, and has not experienced
a recurrence
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developed a CMV infection (CMV antigen: 2/50,000 white
blood cells). After 14 days of intravenous ganciclovir, we
changed the treatment to oral valganciclovir after we had
confirmed the absence of CMV antigen. At 5 weeks after
these treatments were started, all of her skin rash was
covered with scabs, her organ symptoms had disappeared,
and her clinical findings appeared to be completely im-
proved, although her VZV-DNA levels remained high
(8.5 × 103 copies/mL). We continued the oral acyclovir
treatment for another 2 weeks, and she was discharged on
day 86 after the admission; she has not experienced a re-
currence. She was well at 6 months after discharge, and
follow-up PCR testing did not reveal any VZV-DNA.
Discussion
VZV infection is a frequent complication of solid organ
transplantation, although most cases are mild and canbe treated in the outpatient clinic with oral acyclovir.
However, because of their immunocompromised status,
some patients develop a severe illness that is known as
disseminated VZV infection with visceral involvement,
which includes pneumonitis, hepatitis, meningoenceph-
alitis, glomerulonephritis or hemorrhagic complications,
and may result in MOF. Fehr et al. have reported that
the mortality rate for disseminated VZV infection after
renal transplantation is as high as 34 % [1]. Rommelaere
et al. have also recently reported that the mortality rate
of disseminated VZV infection after renal transplant-
ation appears to have decreased since 1995, although no
improvements have been observed over the last 10 years
[11]. We have summarized the recently reported cases of
disseminated VZV infection that led to MOF in Table 2
[12–23]. Immunocompromised patients, including solid
organ or bone marrow transplant recipients, have the
potential to experience a disseminated VZV infection
Table 2 Recently reported cases of varicella-zoster infection that ledto multiple organfailure




Alvite-Canos [12] 43 M Heart transplanatation Hepatitis, Encephalopathy IVIG, Acyclovir Liver
Transplantation,
Alive
verleden [13] 30 M Lung transplantation (hepatic, polmunary, renal
insufficiency
Acyclovir Dead





Spring field C [4] 25 M Crohn disease pulmonary Acyclovir Dead
Hagiya [14] 75 F Acute pancreatitis Pneumonia, Hepatitis Acyclovir, topical vidarabine Dead





Kim [16] 8 M ALL ARDS, Hepatitis DIC,
encephilopathy
Acyclovir, IVIG Alive




Maggi [18] 49 M Healthy Hepatitis hepatectomy Dead




Plesek [20] 26 F spinal demyelination
syndrome
Hepatitis, DIC Acyclovir Dead
Saitoh [21] 47 M Multiple myeloma Hepatitis, DIC, encephalopathy Transfusion Dead
Wiegering [22] 4 M Healthy Puhnonary, Hepatitis, DIC Acyclovir Dead
Roque-Afons [23] 63 F Asthma and sinusitis Fuluminant hepatic failure, DIC Acyclovir, IVIG Liver
transplantation,
Alive
M male, F female, SLE Systemic Lupus Erythematosus, ALL A cute Lympocytic Leukemia, LDLT Living donor liver transplantation, DIC disseminated intravascular
coagulation, IVIG intravenous immunoglobulin
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high once VZV infection leads to MOF. Early diagnosis
and treatment are critical to rescuing these patients, and
liver transplantation should be considered in cases with
fulminant hepatic failure.
We have previously reported our strategies for pre-
venting VZV infection after pediatric LDLT, which was
the largest study regarding VZV infection after pediatric
LDLT [8]. Interestingly, Yamada et al. have also reported
a case of severe disseminated VZV infection that oc-
curred in an immunocompromised host, although that
patient exhibited positive immunity [24]. However, we
still believe that preoperative vaccination and positive
immunity after the transplant are the critical consider-
ations for managing patients after LDLT. We have per-
formed 266 LDLTs between May 2001 and March 2015,
including 36 (14.3 %) cases in which the patients were
between 10-20-years-old at the LDLT; their VZV-IgG
values at the LDLT are shown in Fig. 3. Among these
cases we found that three patients (including this present
case) exhibited relatively low VZV-IgG values and another
one patient did not have VZV-IgG at the LDLT. There-
fore, we currently believe that an additional vaccination
may be added for similar patients before their LDLT,although it is difficult to select an appropriate VZV-IgG
cut-off value for the additional vaccination. Besides, we
are considering about performing re-vaccination for pa-
tients who don’t have positive immunity at 2 years after
their LDLT.
In the present case, the patient had received an epi-
sode of steroid pulse therapy treatment and was receiv-
ing three immunosuppressants (FK, MP, and MMF).
Although it is unknown whether the present case was
primary infection or re-activation of the vaccine strain, it
is possible that re-activation of the vaccine strain might
have led to severe disseminated VZV infection [25–27].
Patients who are receiving a potent immunosuppressant
regimen have a higher risk of latent infection or vaccine
re-activation, and may develop severe illness if VZV
infection occurs, regardless of whether it is primary in-
fection or re-activation. Therefore, an early diagnosis
and treatment are essential to rescue patients with dis-
seminated VZV infection and MOF. In addition, when
VZV infection is suspected in solid organ transplant re-
cipients, it is critical to consider their vaccination his-
tory, anti-VZV titers, and presence of VZV-DNA via
PCR, as this information can help facilitate an early and
accurate diagnosis. If a diagnosis of disseminated VZV
Fig. 3 VZV-IgG values at LDLT in 36 patients received LDLTs at 10–20 years old in our institute. The values are shown as ln VZV-IgG titers. Three
patients, including the patient in the present case, exhibited relatively low antibody titers. There existed one patient who didn’t have VZV-IgG and
not be shown in the figure
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by the patients’condition, and may include hospitalization,
intravenous acyclovir, intravenous immunoglobulin, and
the withdrawal of immunosuppressants.
The primary treatment for disseminated VZV infec-
tion with MOF should address the organ failure and
involve antiviral therapy, including intravenous acyclovir.
In general, the antiviral therapy should be continued until
all skin rashes are covered with scabs, and the organ
symptoms have disappeared. Interestingly, Kronenberg
et al. have reported four cases of disseminated VZV infec-
tion after solid organ transplantation in which the VZV-
DNA levels were monitored via PCR [28]. Among those
cases, one patient exhibited an increase in VZV-DNA
that was accompanied by recurrent gastritis. In our case,
we monitored the VZV-DNA levels via PCR, and they
remained high (8.5 × 103copies/mL), even after all skin
rashes and organ symptoms had completely resolved.
Therefore, we added prophylactic oral acyclovir and
continued monitoring until a decrease in the patient’s
VZV-DNA was observed without any symptoms. This
course appears to have been effective, as the patient has
not experienced a recurrence. Similarly, monitoring for
Epstein Barr virus DNA via PCR is and established
method for prophylaxis and management of those infec-
tions, which are also common after liver transplantation
[29, 30]. However, VZV-DNA monitoring via PCR is not
an established method, although it appears to have the
potential to be an effective biomarker for early diagnosis
of VZV infection. In addition, this monitoring can
evaluate the efficacy of treatment in cases of organ
transplant recipients with severe disseminated VZV in-
fection, especially in patients who have clinical symp-
toms of MOF.In conclusion, although disseminated VZV infection
with MOF after pediatric LDLT is a life-threatening dis-
ease, it can be cured via an early diagnosis and intensive
treatment. In these cases, PCR monitoring of VZV-DNA
is helpful to quickly reach an accurate diagnosis and
evaluate the efficacy of the subsequent treatment.
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